Five months after Arrowhead Pharmaceuticals unveiled topline results for its Phase 2b RNAi candidate in a lipid-related disease, the company on Sunday reported full data at the American College of Cardiology annual meeting.
In the Phase 2b SHASTA-2 trial of plozasiran in patients with severe hypertriglyceridemia (SHTG), the 25 mg dose delivered a 58% reduction in the fasting triglyceride primary endpoint at 48 weeks versus 7% for placebo (p<0.0001), according to a company presentation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.